07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ribonucleotide reductase M1 (RRM1; R1); ribonucleotide reductase M2 (RRM2; R2)

Cardiovascular disease INDICATION: Heart failure Pig studies suggest RRM1 and RRM2 gene therapy could help treat heart failure. In a minipig model of heart failure, intracoronary infusion of an adeno-associated virus (AAV) serotype 6 (AAV6)...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ribonucleotide reductase M1 (RRM1; R1); ribonucleotide reductase M2 (RRM2; R2)

Cardiovascular disease INDICATION: Heart failure Studies in human samples suggest 2-deoxy ATP (dATP) could help treat heart failure. In de-membranated multicellular preparations of ventricular wall tissue from patients with end-stage heart failure, treatment with dATP...
08:00 , Feb 19, 2015 |  BC Innovations  |  Targets & Mechanisms

Ace of hearts

Less than two years after coming out of stealth mode, University of Washington spinout Beat BioTherapeutics Corp. has shown preclinical proof of concept for its heart failure gene therapy designed to provide dATP as an...
14:51 , Feb 13, 2015 |  BC Innovations  |  Targets & Mechanisms

Ace of hearts

Less than two years after coming out of stealth mode, University of Washington spinout Beat BioTherapeutics Corp. has shown preclinical proof of concept for its heart failure gene therapy designed to provide dATP as an...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

BEATBio management update

Beat BioTherapeutics Corp. , Seattle, Wash.   Business: Cardiovascular   Hired: Sam Teichman as CMO and a director  ...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Financial News

Beat BioTherapeutics completes venture financing

Beat BioTherapeutics Corp. , Seattle, Wash.   Business: Cardiovascular   Date completed: 4/16/13   Type: Venture financing   Raised: $2.5 million   Investors: CET Capital Partners; W Fund   Note: The financing was debt, according...
00:28 , Apr 18, 2013 |  BC Extra  |  Financial News

Beat raises $2.5 million in seed funding

Cardiovascular company Beat BioTherapeutics Corp. (Seattle, Wash.) came out of stealth mode to announce it raised $2.5 million in seed funding from CET Capital Partners. W Fund also participated. According to an SEC filing, the...